Cortexyme, Inc. Company Profile

05:00 EDT 19th June 2018 | BioPortfolio

Based in South San Francisco, California, Cortexyme is a privately held, clinical-stage pharmaceutical company developing therapeutics to alter the course of Alzheimer’s and other degenerative disorders. Cortexyme is targeting a specific, undisclosed infectious pathogen tied to neurodegeneration and chronic inflammation in humans and animal models. The company’s lead compound, COR388, is the subject of an ongoing phase 1 clinical trial; additional proprietary small molecules are moving forward in preclinical development. Cortexyme’s investors include Pfizer, Takeda Ventures, Lamond Family, Dolby Family Ventures, Breakout Ventures, and Breakout Labs. For more information on Cortexyme, visit

News Articles [7 Associated News Articles listed on BioPortfolio]

Alzheimer’s Company Cortexyme Closes $76 Million Series B Financing Round with Pfizer, Takeda and...

South San Francisco-based Cortexyme closed on a $76 million Series B financing round.

Cortexyme closes $76mm Series B round

Cortexyme Inc. (neurodegenerative disease therapeutics with a focus on Alzheimer's) raised $76mm in a Series B round from new investors Sequoia Capital, Vulcan Capital, Verily Life Sciences, EPIQ Capi...

Sequoia leads Cortexyme's $76M series B

Firm targeting potential bacterial role in Alzheimer’s gets $76 million Series B

Cortexyme has also finished enrolling healthy volunteers in the

Bacterial brain

Preclinical and clinical data supporting bacterial pathogenesis of Alzheimer’s brought Sequoia onto Cortexyme’s $76 million series B.

Cortexyme Completes $76 Million Series B Financing and Provides Update on Clinical Development Progress

– Cortexyme has successfully completed key components of its phase 1 clinical development program for lead compound COR388 – Cortexyme, Inc., a clinical-stage pharmaceutic...

Cortexyme Initiates Phase 1 Clinical Development of COR388, a Promising Potential Treatment for Alzheimer’s and Other Degenerative Diseases

-- Cortexyme’s lead compound represents a promising new approach to addressing Alzheimer’s -- -- First two studies in the phase 1 trial program will enroll a total ...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [1 Associated Companies listed on BioPortfolio]

Cortexyme, Inc.

Based in South San Francisco, California, Cortexyme is a privately held, clinical-stage pharmaceutical company developing therapeutics to alter the course of Alzheimer’s and ...

More Information about "Cortexyme, Inc." on BioPortfolio

We have published hundreds of Cortexyme, Inc. news stories on BioPortfolio along with dozens of Cortexyme, Inc. Clinical Trials and PubMed Articles about Cortexyme, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cortexyme, Inc. Companies in our database. You can also find out about relevant Cortexyme, Inc. Drugs and Medications on this site too.

Quick Search


Relevant Topics

Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...

Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...

Corporate Database Quicklinks

Searches Linking to this Company Record